Search clinical trials for: Anlotinib plus AK105

Total 6313 results

Guangzhou Institute of Respiratory Disease

Not yet recruiting

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
Akeso

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Hyperlipidemia

China
Sichuan Cancer Hospital and Research Institute

Recruiting

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (ALTER-GO-020)

Gynecological Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Non-small Cell Lung Cancer

China
Peking University People's Hospital
Peking University First Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Unknown

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma (CSSG-03)

Quality of Life | Advanced Cancer | Chordoma | Effect of Drugs

China
XSpray Microparticles

Completed

Pharmacokinetic Comparison of XS003 and Tasigna

Healthy

United Kingdom
Akeso

Not yet recruiting

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Akeso

Recruiting

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Shanghai Chest Hospital

Unknown

First-line Combination Treatment Based on Anlotinib

Lung Cancer | Advanced Stage

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Thyroid Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Jinglong Chen

Recruiting

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Hepatocellular Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (ALTER-H-004)

Hepatocellular Carcinoma | Anlotinib | TACE

China
University of Pittsburgh
OSI Pharmaceuticals

Completed

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Tianjin Medical University Second Hospital

Recruiting

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Bladder Cancer

China
Hunan Cancer Hospital

Recruiting

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Ovarian Cancer

China
Akeso
Akeso Tiancheng, Inc

Completed

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Rigshospitalet, Denmark
Curasight ApS

Completed

uPAR PET/CT for Preoperative Staging of Breast Cancer Patients

Breast Cancer

Denmark
Guangzhou University of Traditional Chinese Medicine
Guangdong Provincial Hospital of Traditional Chinese Medicine

Recruiting

Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Liu Zhenhua

Not yet recruiting

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Huashan Hospital

Active, not recruiting

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

Malignant Glioma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Gynecological Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Advanced Acral Malignant Melanoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Lung Cancer

China
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Hubei Cancer Hospital

Not yet recruiting

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Breast Cancer
Sun Yat-sen University

Not yet recruiting

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma
Qure Healthcare, LLC
Lineagen

Completed

Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study

Intellectual Disability | Developmental Delay

United States
University of Louisville
James Graham Brown Cancer Center

Terminated

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Small Cell Lung Cancer Extensive Stage
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
University of South Carolina
National Cancer Institute (NCI); American Cancer Society, Inc.

Completed

Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors

Breast Cancer

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals

Completed

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Healthy
Sheba Medical Center

Completed

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Israel
Samsung Medical Center

Completed

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Metastatic Melanoma With KIT Aberration

Korea, Republic of
Gangnam Severance Hospital

Completed

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Primary Open-angle Glaucoma
Rigshospitalet, Denmark

Unknown

uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer

Neoplasms | Neoplasms by Site | Head and Neck Neoplasms | Oral Cancer | Oropharyngeal Cancer | Cancer of Mouth

Denmark
Rigshospitalet, Denmark

Completed

Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

Breast Cancer | Prostate Cancer | Urinary Bladder Cancer

Denmark
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
Janssen-Cilag, S.A.

Completed

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
The University of Tennessee, Knoxville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Cherokee...

Completed

Implementing Prevention Plus for Childhood Overweight and Obesity in Food Secure and Insecure Families

Obesity | Childhood Obesity

United States

Search clinical trials for: Anlotinib plus AK105

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations